Opportunity costs in drug development. This presentation demonstrates how to estimate the opportunity costs of false positives and false negatives in pharmaceutical R&D decision making. While the industry fears false negatives, false positives are demonstrated to be much more costly to the organization.
7. Rational Optimism
By placing tasks in parallel to reduce cycle time we
inadvertently:
Increased R&D costs
Increased late-stage attrition rates
Increased expected time to market
8. Rational Optimism
By placing tasks in parallel to reduce cycle time we
inadvertently:
Increased R&D costs
Increased late-stage attrition rates
Increased expected time to market
Lendrem DW, Lendrem BC Torching the Haystack: Modelling fast-fail strategies in drug
development. Drug Discov Today. 2013 Apr;18(7-8):331-6.
http://dx.doi.org/10.1016/j.drudis.2012.11.011
Lendrem DW, Lendrem BC The Development Speed Paradox: Can increasing development
speed reduce R&D productivity? Drug Discov Today. 2014 Mar;9(3):209-214
http://dx.doi.org/10.1016/j.drudis.2013.09.002
10. Rational Optimism
It is more important to do the right science than to do
the wrong science quickly.
Build opportunities to kill projects earlier in the
development cycle.
Focus on tests that prevent projects from entering the
development process.
Focus on tests that allow elimination of projects early
in the development process.
12. Rational Optimism
Progression Bias
terminations are viewed as losses and project teams are loss-
averse
sunk-costs fallacy terminating a project risks losing investment
that has already been lost
marginal cost associated with a decision to continue development
may seem trivial compared to the losses associated with
terminating a potential NTD
organizational and market incentives to load the pipeline with
promising candidates
Progression bias leads to continued development even in
the light of strong evidence supporting termination.
13. Rational Optimism
Rational Optimism
Continued pursuit of a line of research in the knowledge that it is
likely to be successful.
14. Rational Optimism
Rational Optimism
Continued pursuit of a line of research in the knowledge that it is
likely to be successful.
Mindless Optimism
Continued pursuit of a line of research in the hope that it will be
successful.
19. Rational Optimism
Opportunity Costs:
Loss due to false negatives = B
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
20. Rational Optimism
Opportunity Costs:
Loss due to false negatives = B
Loss due to false positives = C
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
21. Rational Optimism
Opportunity Costs:
Loss due to false negatives = B
Loss due to false positives = CxA
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
25. Rational Optimism
So?
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
Cost of False Positives
when 留 = 67%
Cost of False Negatives
when 硫 =10%
mindless
optimism
rational
optimism
vs
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
mindless
optimism
rational
optimism Cost of False Negatives
when 硫 =20%
Cost of False Positives
when 留 = 67%
vs
The false negative rate has to be rather high before it outweighs
the cost of false positives!
29. Rational Optimism
So?
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
Cost of False Negatives
when 硫 =20%
Cost of False Positives
when 留 = 67%
mindless
optimism
rational
optimism
vs
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
Cost of False Negatives
when 硫 =20%
mindless
optimism
rational
optimism
vs
Early Development Late Development
30. Rational Optimism
So?
We fear false negatives, but the opportunity costs of false positives
are huge.
Terminating projects frees up R&D resources to pursue other
prospects.
Thinking about opportunity costs allows project teams to reframe
termination decisions as prospective future gains.
32. Rational Optimism
Richard Peck (Roche)
Stephen Senn (CRP Sant辿)
Simon Day (MHRA)
John Isaacs (MRG)
John Loughlin (MRG)
NIHR Newcastle BRC
33. Rational Optimism
Richard Peck (Roche)
Stephen Senn (CRP Sant辿)
Simon Day (MHRA)
John Isaacs (MRG)
John Loughlin (MRG)
Clare Lendrem (AHG)
NIHR Newcastle BRC
#8: As a result, the industry became really slick at delivering late-stage failures to the market place, precipitating the current R&D productivity crisis.
#9: As a result, the industry became really slick at delivering late-stage failures to the market place, precipitating the current R&D productivity crisis.